Inventiva S.A.
NASDAQ:IVABiotechnology
Healthcare
$3.39 +0.42%
+$0.02 today
- Market cap
- $176.22M
- Beta
- 0.88
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.56
52W Low $2.85High $7.98
Volume 3.54M
Average 0.45M
Income Statement
Follow revenue through to earnings.
Revenue
$4.48M
FY 2025 · Annual
-51.3% YoYOperating Income
-$130.95M
FY 2025 · Annual
Net Income
-$340.16M
FY 2025 · Annual
Income Statement
EUR
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.19M | 12.18M | 17.48M | 9.2M | 4.48M |
| Cost of Revenue | 1.02M | 995K | (23K) | 3.88M | 2.8M |
| Gross Profit | 4.19M | 17.06M | 17.5M | 9.2M | 1.51M |
| Gross Margin | 100.0% | 140.1% | 100.1% | 100.0% | 33.7% |
| Research & Development | 48.45M | 60.47M | 110.01M | 90.88M | 83.61M |
| Selling, General & Admin | 11.52M | 15.5M | 15.61M | 17.1M | 53.89M |
| Operating Expenses | 56.31M | 74.17M | 120.19M | 106.76M | 137.37M |
| Depreciation & Amortization | 858K | 870K | 2.6M | 5.2M | 2.8M |
| EBITDA | (52.76M) | (56.29M) | (102.04M) | (166.53M) | (128.15M) |
| EBITDA Margin | -1258.0% | -462.2% | -583.9% | -1810.4% | -2858.6% |
| Operating Income | (52.11M) | (57.11M) | (102.71M) | (97.56M) | (130.95M) |
| Operating Margin | -1242.6% | -468.9% | -587.7% | -1060.6% | -2921.0% |
| Interest Income | 57K | 390K | 945K | 1.14M | 2.83M |
| Interest Expense | 138K | 707K | 5.18M | 12.18M | 32.3M |
| Other Income / Expenses | 2.84M | 2.82M | (7.11M) | (86.34M) | (211.38M) |
| Income Before Tax | (49.27M) | (54.29M) | (109.82M) | (183.9M) | (342.33M) |
| Pre-Tax Margin | -1174.8% | -445.8% | -628.4% | -1999.4% | -7636.1% |
| Income Tax Expense | 364K | (20K) | 607K | 313K | 22K |
| Net Income | (49.64M) | (54.27M) | (110.43M) | (184.21M) | (340.16M) |
| Net Margin | -1183.5% | -445.6% | -631.8% | -2002.7% | -7587.8% |
| EPS (Basic) | (1.27) | (1.31) | (2.43) | (3.54) | (1.82) |
| EPS (Diluted) | (1.27) | (1.31) | (2.43) | (3.54) | (1.82) |
| 39.17M | 41.45M | 45.35M | 51.98M | 186.8M | |
| 39.17M | 41.45M | 45.35M | 51.98M | 186.8M |
IVA Earnings Waterfall · TTM
NASDAQ:IVA · Revenue to Net Income
Key Ratios
EPS$-5.44
Gross Margin-952.9%
Net Margin-155629.2%
P/E Ratio-1.2
P/S Ratio21932.8
Analysis
$13.7M of revenue converted into -$537.0M of net income for the selected period. Gross margin is -952.9% and net margin is -155629.2%, showing how much revenue survives after costs and taxes. EPS is $-5.44, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Oct 27, 2026 | |
| 6-K | 6-K filing | Oct 6, 2026 | |
| 6-K | 6-K filing | Sep 28, 2026 | |
| 6-K | 6-K filing | Sep 3, 2026 | |
| 6-K | 6-K filing | Sep 1, 2026 |
How much revenue does IVA generate?
Inventiva S.A. (IVA) reported $4.48M of revenue in fiscal 2025.
Is IVA profitable?
Inventiva S.A. (IVA) reported -$340.16M of net income, with a net margin of -7587.8%.
Continue the stock analysis
Jump to another research area for this company.